Physicians from University Foot & Ankle Institute, in collaboration with Regenative Labs, announced the publication of a peer-reviewed observational cohort study evaluating the use of umbilical cord connective tissue allografts for tissue supplementation in patients with posterior tibial tendon degeneration who failed standard conservative care.
The study reports improvements in pain, function, and quality of life following percutaneous application of Wharton’s Jelly tissue allografts in a treatment-resistant patient population.
From baseline to final follow-up, patients receiving a single application demonstrated a 48.32% improvement in pain scores, with statistically significant reductions observed in NPRS values. Patients receiving two applications demonstrated comparable improvements in pain and statistically significant improvements in quality-of-life measures. No adverse events were reported.
The Wharton’s Jelly tissue allografts used in the study were processed and distributed by Regenative Labs, a U.S.-based tissue processing company specializing in compliant human connective tissue allografts.
“This publication reflects Regenative Labs’ commitment to clinician-driven, IRB-reviewed research that prioritizes safety, transparency, and responsible data collection,” said Tyler Barrett, CEO of Regenative Labs and a co-author on the study. “Our role is to support physicians with compliant tissue processing and research infrastructure so meaningful clinical questions can be evaluated rigorously.”
Physicians from University Foot & Ankle Institute, in collaboration with Regenative Labs, announced the publication of a peer-reviewed observational cohort study evaluating the use of umbilical cord connective tissue allografts for tissue supplementation in patients with posterior tibial tendon degeneration who failed standard conservative...
Physicians from University Foot & Ankle Institute, in collaboration with Regenative Labs, announced the publication of a peer-reviewed observational cohort study evaluating the use of umbilical cord connective tissue allografts for tissue supplementation in patients with posterior tibial tendon degeneration who failed standard conservative care.
The study reports improvements in pain, function, and quality of life following percutaneous application of Wharton’s Jelly tissue allografts in a treatment-resistant patient population.
From baseline to final follow-up, patients receiving a single application demonstrated a 48.32% improvement in pain scores, with statistically significant reductions observed in NPRS values. Patients receiving two applications demonstrated comparable improvements in pain and statistically significant improvements in quality-of-life measures. No adverse events were reported.
The Wharton’s Jelly tissue allografts used in the study were processed and distributed by Regenative Labs, a U.S.-based tissue processing company specializing in compliant human connective tissue allografts.
“This publication reflects Regenative Labs’ commitment to clinician-driven, IRB-reviewed research that prioritizes safety, transparency, and responsible data collection,” said Tyler Barrett, CEO of Regenative Labs and a co-author on the study. “Our role is to support physicians with compliant tissue processing and research infrastructure so meaningful clinical questions can be evaluated rigorously.”
Copy to clipboard 
